Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJOG14720L brigatinib versus brigatinib plus carboplatin/pemetrexed in untreated ALK-rearranged non-squamous NSCLC
jRCTs041210103Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brigatinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-free survival. Started Jan 2022; status: active, not recruiting.
02
Drugs
brigatinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041210103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210103.